

**Regular Meeting of the Board of Directors
Minutes
June 12, 2024
8:00am – 10:00am
Via Zoom**

MEMBERS PRESENT: Patricia Finn, M.D. (Chairperson)
Christopher Arndt, M.D.
James Chodosh, M.D.
Chandra Cullen, M.D.
Dale Dekker, AIA
Nancy Joste, M.D.
Elizabeth Lawrence, M.D.
Michael Richards, M.D.
Aimee Smidt, M.D.
Mark Unruh, M.D.

MEMBERS ABSENT: N/A

OFFICERS PRESENT: Gary Mlady, M.D., Interim President & CEO
Jill Klar, COO
Jennifer Phillips, M.D., CMO
Jared Udall, CFO
Cory McDowell, Secretary

OFFICERS ABSENT: N/A

OTHERS PRESENT: Renee Ayala
Andy Baatz
Laura Comstock
Richard Fortescue
Kristin Gates
Chris Hamilton
Helen Villarreal-Nielsen
Elizabeth Muller
John-Paul Montoya
Mary Swanson
Betty Chang, MD
Rebecca Napier
Erica Richards
Quinn Mander
Debra Padilla
Jessa Zenor-Mckelvey
Laura Lerdall (Scribe)

GUESTS: N/A

I.	Call to Order and Confirmation of Quorum (<i>Patricia Finn, M.D.</i>)	Action
	<p>Dr. Patricia Finn called the meeting to order at 8:00am.</p> <p>Quorum was noted.</p>	
II.	Opening Comments (<i>Patricia Finn, M.D.</i>)	Information
	<p>Dr. Patricia Finn welcomed attendees to the meeting.</p> <p>Dr. Finn recognized Aimee Smidt, MD for a lead article in the New England Journal of Medicine.</p> <p>Dr. Finn invited attendees to “Dessert with the Dean” events that will occur on a regular basis.</p>	
III.	Approval of Consent Agenda (<i>Patricia Finn, M.D.</i>)	Action
	<p>Dr. Patricia Finn presented the following items for approval as part of the Consent Agenda:</p> <ul style="list-style-type: none"> A. Finance Committee Meeting Minutes for: <ul style="list-style-type: none"> 1. April 3, 2024 B. Operations Committee Minutes <ul style="list-style-type: none"> 1. March 27, 2024 C. COO/CMO Report 	<p>Dr. Patricia Finn requested a motion to approve the consent agenda. Dr. James Chodosh made the motion & Dr. Christopher Arndt seconded the motion. Motion carried with no discussion or opposition.</p>
IV.	Approval of Board Meeting Minutes (<i>Patricia Finn, M.D.</i>)	Action
	<p>Dr. Patricia Finn presented the UNMMG Board Meeting minutes for the April 10, 2024 meeting for approval.</p>	<p>Dr. Patricia Finn requested a motion to approve the April 10, 2024 meeting minutes. Dr. James Chodosh made a motion to approve and Dr. Mark Unruh seconded the motion. Motion carried with no opposition or discussion.</p>
V.	Public Comment	Information
	<p>Dr. Patricia Finn asked if there was any public comment for this meeting.</p>	

	No public comment was received for this meeting.	
VI.	Administrative Reports	Action
	<p>A. Chief Financial Officer Report (<i>Jared Udall</i>)</p> <p>1. Financial & Revenue Cycle Report (Action) Mr. Udall presented Financial Highlights through April 2024, which was a record-breaking month, and reviewed slides that were provided in advance to the Board. Call-out went to the Payor Mix and increase in Medicaid.</p> <p>Investment income was clarified by Mr. Udall that it only becomes income when we realize it. So, it's a fair amount of equity until those bonds and investments come to maturity and either sell or get reinvested. Regular statements from investment firms show growth, but they stay in the reserves when they get realized. They are not applied or distributed anywhere.</p> <p>Mr. Udall went on to explain that the yield from long-term investments is applied to management company expenses. So, from that perspective, the departments do get the benefit of that money sitting in the bank.</p> <p>Discussion followed on opportunities for attention going forward and clarifying the enrollment and disenrollment of Medicaid with the state.</p> <p>B. Chief Executive Officer Report (<i>Gary Mlady, M.D.</i>) (Information) Interim President and CEO Dr. Gary Mlady presented slides to the attendees which were provided to the Board in advance of the meeting.</p> <p>Dr. Mlady acknowledged Mary Schimmel, UNMMG Quality Manager who recently presented at the NM APIC Conference in April on Infection Control in the Reproductive Health Setting.</p> <p>Additional acknowledgement went to Jill Klar, UNMMG COO who was recognized as an ICON Top 50 COOs.</p> <p>Dr. Mlady also gave kudos to the Revenue Cycle Team who accomplished a record for cash collections and gross revenue in April. Continuing revenue cycle with the optimization of IDX has been very positive. Users can do a lot of things more efficiently than they did before which is fantastic!</p> <p>Dr. Mlady stated that the recent Press Ganey survey that was just completed had 85% response rate which was the highest rate in the Health System organization.</p> <p>The Medical Group Administrative offices were planning to move from 933 to 800 Bradbury which will give us an opportunity to hold future Board Meetings in that space with better parking. Dr. Mlady thanked the team that organized the move seamlessly.</p> <p>The Special Care Dental Clinic will be expanding soon as well as the ASC. The Dental Clinic has two operating rooms and supports our UNMG Dental Program and UNG Health Special Care Dental Services by providing surgical services to patients not requiring hospitalization.</p>	<p>Dr. Patricia Finn called for a motion to accept the Financial and Revenue Cycle Report which was so moved by Dr. Christopher Arndt and seconded by Dr. James Chodosh. The motion was passed with no objections.</p>

Coming in the fall School Based Health Clinic will open a new facility at West Mesa High School that can provide services to students there, funded by the state.

LoboSTEPPS is also coming soon.

C. Physician Advisory Group (PAG) Update (*Elizabeth Lawrence, M.D.*) (Information)

Dr. Lawrence provided an update on recent PAG meetings and presented a slide deck for attendees that also included revisiting the PAG Mission as well as some PAG growing pains. The committee will be holding in-person meetings as well.

D. Privilege Sets (*Jennifer Phillips, M.D.*) (Action)

There were no Privilege Sets for this meeting which is a standing item in Open Session.

E. CMO Quality Report (*Jennifer Phillips, MD*)

Dr. Phillips presented the CMO Quality report for approval by the Board which was provided to them in advance of the meeting.

Dr. Phillips covered Clinic statistics for UOP Quality Metrics, Medication Reconciliation, Hand Washing trends, and Patient Experience key drivers.

Next steps for Patient Experience include the continuation of monitoring Key Performance Indicators and comments monthly, increasing opportunities for reporting and discussing metrics, solicit single-question surveys, focus on FY25 Quality and Accountability Plan, increase partnership with Patient Experience Department to include quarterly reports and presentations with feedback from press Ganey and continue to build patient experience into standard work to ensure sustainment.

A call for a motion was made to accept the CMO Quality Report was made. Dr. Christopher Arndt made the motion and Dr. James Chodosh seconded the motion. The motion carried with no discussion or objection.

VII. Whitecap Funds Flow Update (*Michael Richards, MD*)

Information

Dr. Michael Richards updated the attendees to ensure everyone is aware of the engagement with a healthcare consulting company called Whitecap that we've had for 20 years and they are working with us on looking at our macro funds flow across the clinical delivery system.

There is about \$300M of internal movement of funds as we purchase services back and forth across various components and MOUS. Part of what they are trying to help us understand is sources and use of all our clinical revenues and find ways for us to streamline that process of company transfers of money and purchases of services. Additionally, that also gives us an opportunity to benchmark ourselves against our other academic peers, to look at the support that we're getting from the hospital to the School of Medicine, or for clinical services and for us to also look to make sure that those transactions are appropriately documented.


	<p>A large second part of this is a School of Medicine compensation, because most of the transaction funds, most of it, falls into 2 buckets and they're both related to provider services. So, the first biggest enter company transfer is this one from the Medical Group to the School of Medicine (a provider-related transfer). Because the School of Medicine really employs the physicians. But the collections happen in Medical Group.</p> <p>Secondly is also provider-related is the funds that come from the Hospital to support provider services and those are both about \$175M each. So, we are ensuring that we're market competitive and have clear guiding principles.</p> <p>The portion of the Whitecap engagement is led by Dean Finn and the Council of Chairs. The engagement will result in some major restructuring of the current thinking of inter-company funds flow and likely will result in some significant changes to the compensation plan. But we are in the design phase now and a little early to see exactly how this will land. We will use the cost of production model to drive this, which means the mission areas and the contribution of the providers and the divisions and the departments all must be completely funded and how the revenues or the resources need to be provided to that department division and individual faculty members.</p> <p>Questions ensued regarding the timeframe. The timeframe of one year to put the model in place is currently at the half-way point. When the model is in place it's a 5-year process. This length is planned so as not to disrupt the ability to deliver clinical services and department functions.</p> <p>Further discussion followed. This topic will be revisited.</p>	
VIII.	Vote to go into Executive Session (Patricia Finn, M.D.)	Action
	<p>Vote to go into Executive Session for the following purposes:</p> <p><i>A. Discussion and, where appropriate, determination of matters involving information, proceedings, or actions covered by the confidentiality protections of the New Mexico Review Organization Immunity Act, § 41-91-1 et seq., NMSA 1978, as provided in Section 5(10) of the UNMMG's Open Meetings Policy.</i></p> <p><i>B. Portions of meetings of the Board of Directors where strategic and long-range business plans, trade secrets, or institutional compliance program matters are discussed.</i></p> <p><i>C. Discussion of limited personnel matters (specifically, discussion of investigation and consideration of complaints against individual employees) and matters subject to attorney-client privilege pertaining to threatened or pending litigation, governmental investigation, administrative proceeding, arbitration proceeding, mediation, in which the Corporation is or may be before a participant.</i></p>	<p>Dr. Patricia Finn requested a motion to convene into Executive Session. Dr. James Chodosh made the motion and Dr. Christopher Arndt seconded. The motion passed with no objection.</p>
IX.	Vote to Reconvene into Open Session (Patricia Finn, M.D.)	Action
	<p><i>A. Certification that only those matters described in Agenda Item VIII above were discussed in Executive Session and, if necessary, final action with regard to those matters will be taken in Open Session.</i></p>	<p>The motion to reconvene and certify</p>

		Executive Session matters was motioned and approved by the quorum.
X.	Meeting Adjourned (Patricia Finn, M.D.)	Action
	There being no further business, Patricia Finn, M.D. requested a motion to adjourn the Regular Session of the UNM Medical Group Board of Directors at 10:03am.	Dr. Patricia Finn requested a motion to adjourn which was motioned and approved by the quorum.



 Mr. Cory McDowell, Board Secretary

8/14/24
 Date



 Ms. Laura Lerdall, Scribe

8.14.24
 Date